Cargando…

Treatment of Functional Hypogonadism Besides Pharmacological Substitution

A dichotomic distinction between “organic” and “functional” hypogonadism is emerging. The former is an irreversible condition due to congenital or “acquired” “organic” damage of the brain centers or of the testis. Conversely, the latter is a potentially reversible form, characterized by borderline l...

Descripción completa

Detalles Bibliográficos
Autores principales: Corona, Giovanni, Rastrelli, Giulia, Morelli, Annamaria, Sarchielli, Erica, Cipriani, Sarah, Vignozzi, Linda, Maggi, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Sexual Medicine and Andrology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308235/
https://www.ncbi.nlm.nih.gov/pubmed/31496147
http://dx.doi.org/10.5534/wjmh.190061
_version_ 1783548946540396544
author Corona, Giovanni
Rastrelli, Giulia
Morelli, Annamaria
Sarchielli, Erica
Cipriani, Sarah
Vignozzi, Linda
Maggi, Mario
author_facet Corona, Giovanni
Rastrelli, Giulia
Morelli, Annamaria
Sarchielli, Erica
Cipriani, Sarah
Vignozzi, Linda
Maggi, Mario
author_sort Corona, Giovanni
collection PubMed
description A dichotomic distinction between “organic” and “functional” hypogonadism is emerging. The former is an irreversible condition due to congenital or “acquired” “organic” damage of the brain centers or of the testis. Conversely, the latter is a potentially reversible form, characterized by borderline low testosterone (T) levels mainly secondary to age-related comorbidities and metabolic derangements, including metabolic syndrome (MetS). Life-style modifications, - here reviewed and, when possible, meta-analyzed -, have documented that weight-loss and physical exercise are able to improve obesity-associated functional hypogonadism and its related sexual symptoms. A rabbit experimental model, of MetS originally obtained in our lab, showed that endurance training (PhyEx) completely reverted MetS-induced hypogonadotropic hypogonadism by reducing hypothalamus inflammation and testis fibrosis eventually allowing for a better corpora cavernosa relaxation and response to sildenafil. Physicians should strongly adapt all the reasonable strategies to remove/mitigate the known conditions underlying functional hypogonadism, including MetS and obesity. Physical limitations, including reduced muscle mass and increased fat mass, along with low self-confidence, also due to the sexual problems, might limit a subject's propensity to increase physical activity and dieting. A short term T treatment trial, by improving muscle mass and sexual function, might help hypogonadal obese patients to overcome the overfed, inactive state and to become physically and psychologically ready for changing their lifestyle.
format Online
Article
Text
id pubmed-7308235
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Korean Society for Sexual Medicine and Andrology
record_format MEDLINE/PubMed
spelling pubmed-73082352020-07-01 Treatment of Functional Hypogonadism Besides Pharmacological Substitution Corona, Giovanni Rastrelli, Giulia Morelli, Annamaria Sarchielli, Erica Cipriani, Sarah Vignozzi, Linda Maggi, Mario World J Mens Health Review Article A dichotomic distinction between “organic” and “functional” hypogonadism is emerging. The former is an irreversible condition due to congenital or “acquired” “organic” damage of the brain centers or of the testis. Conversely, the latter is a potentially reversible form, characterized by borderline low testosterone (T) levels mainly secondary to age-related comorbidities and metabolic derangements, including metabolic syndrome (MetS). Life-style modifications, - here reviewed and, when possible, meta-analyzed -, have documented that weight-loss and physical exercise are able to improve obesity-associated functional hypogonadism and its related sexual symptoms. A rabbit experimental model, of MetS originally obtained in our lab, showed that endurance training (PhyEx) completely reverted MetS-induced hypogonadotropic hypogonadism by reducing hypothalamus inflammation and testis fibrosis eventually allowing for a better corpora cavernosa relaxation and response to sildenafil. Physicians should strongly adapt all the reasonable strategies to remove/mitigate the known conditions underlying functional hypogonadism, including MetS and obesity. Physical limitations, including reduced muscle mass and increased fat mass, along with low self-confidence, also due to the sexual problems, might limit a subject's propensity to increase physical activity and dieting. A short term T treatment trial, by improving muscle mass and sexual function, might help hypogonadal obese patients to overcome the overfed, inactive state and to become physically and psychologically ready for changing their lifestyle. Korean Society for Sexual Medicine and Andrology 2020-07 2019-08-29 /pmc/articles/PMC7308235/ /pubmed/31496147 http://dx.doi.org/10.5534/wjmh.190061 Text en Copyright © 2020 Korean Society for Sexual Medicine and Andrology http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Corona, Giovanni
Rastrelli, Giulia
Morelli, Annamaria
Sarchielli, Erica
Cipriani, Sarah
Vignozzi, Linda
Maggi, Mario
Treatment of Functional Hypogonadism Besides Pharmacological Substitution
title Treatment of Functional Hypogonadism Besides Pharmacological Substitution
title_full Treatment of Functional Hypogonadism Besides Pharmacological Substitution
title_fullStr Treatment of Functional Hypogonadism Besides Pharmacological Substitution
title_full_unstemmed Treatment of Functional Hypogonadism Besides Pharmacological Substitution
title_short Treatment of Functional Hypogonadism Besides Pharmacological Substitution
title_sort treatment of functional hypogonadism besides pharmacological substitution
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308235/
https://www.ncbi.nlm.nih.gov/pubmed/31496147
http://dx.doi.org/10.5534/wjmh.190061
work_keys_str_mv AT coronagiovanni treatmentoffunctionalhypogonadismbesidespharmacologicalsubstitution
AT rastrelligiulia treatmentoffunctionalhypogonadismbesidespharmacologicalsubstitution
AT morelliannamaria treatmentoffunctionalhypogonadismbesidespharmacologicalsubstitution
AT sarchiellierica treatmentoffunctionalhypogonadismbesidespharmacologicalsubstitution
AT ciprianisarah treatmentoffunctionalhypogonadismbesidespharmacologicalsubstitution
AT vignozzilinda treatmentoffunctionalhypogonadismbesidespharmacologicalsubstitution
AT maggimario treatmentoffunctionalhypogonadismbesidespharmacologicalsubstitution